Endothelial Exosomes Emerge as Precision Tools for Cardiometabolic Disease

A sweeping new review published in the Journal of Translational Medicine argues that tiny vesicles shed by the cells lining our blood vessels may hold the key to diagnosing and treating one of medicine’s most stubborn challenges: cardiometabolic multimorbidity, the coexistence of two or more interrelated conditions such as hypertension, stroke, ischemic heart disease, atherosclerosis, and type 2 diabetes. The work, led by Fei Tang, Shi-Chao Zhu, Hui-Min Zhou, Min Liu, Wen-Xiao Yuan, and corresponding author Xue-Wen Qiu of the Department of Pharmacy at Chongqing General Hospital, Chongqing Academy of Medical Sciences and Chongqing University, synthesizes a rapidly growing body of mechanistic evidence into a unifying framework the authors call the exosomes-X axis.

Cardiometabolic multimorbidity has become an increasingly urgent global public health concern. Patients rarely develop these disorders in isolation; hypertension begets atherosclerosis, diabetes accelerates vascular injury, and stroke and ischemic heart disease frequently follow. What ties this cluster together, the review emphasizes, is endothelial dysfunction, a failure of the single-cell layer that lines every blood vessel in the body. The endothelium is far more than a passive barrier. It regulates vascular tone through nitric oxide signaling, controls inflammatory adhesion of immune cells, maintains the integrity of barriers such as the blood-brain barrier, and orchestrates tissue repair. When it falters, the consequences ripple across the entire cardiovascular and metabolic system, which is why endothelial dysfunction serves both as an early warning marker and as a central driver of disease progression.

The review’s central proposition is that endothelial cells communicate their state of health, or distress, to distant tissues through extracellular vesicles, particularly exosomes. These nanoscale membrane-bound particles, typically ranging from roughly 30 to 150 nanometers in diameter, are released when multivesicular bodies within the cell fuse with the plasma membrane. Far from being cellular debris, exosomes are carefully sorted packages carrying a molecular cargo that mirrors and modulates the physiology of the parent cell. Endothelial-derived exosomes, abbreviated ECs-exo in the review, transport microRNAs, long non-coding RNAs, circular RNAs, proteins, and lipids to recipient cells, where these molecules can reprogram gene expression, alter signaling pathways, and shift cellular behavior.

The mechanistic detail assembled by the Chongqing team is considerable. Dysregulated exosomal cargos, the authors report, propagate vascular inflammation, insulin resistance, and fibrotic remodeling across cardiometabolic disease. Inflammatory cascades involving Toll-like receptor 4 signaling, adhesion molecules such as ICAM-1 and VCAM-1, and mediators like high mobility group box 3 protein and oxidized low-density lipoprotein are amplified or dampened by the exosomal payload. Signaling hubs including the MAPK and ERK pathways, protein kinase C-alpha, phosphatase and tensin homologue, forkhead box protein O1, and hypoxia-inducible factor-1alpha appear repeatedly in the regulatory networks the review describes. Hypoxia-inducible factor-1alpha in particular links oxygen deprivation, a hallmark of ischemic heart disease and stroke, to exosomal reprogramming that can either aggravate injury or, under the right conditions, promote adaptation and repair.

Not all endothelial exosomes are harbingers of disease. The review highlights a protective side of the axis: exosomal microRNAs released by healthy endothelium support vascular repair and suppress pathological inflammation. Endothelial progenitor cells, which participate in vessel regeneration, release vesicles enriched with pro-angiogenic and anti-inflammatory microRNAs that can enhance nitric oxide production, reduce endothelin-1-driven vasoconstriction, and stabilize vulnerable plaques. Molecules such as heme oxygenase-1, Krüppel-like factor 2, and vascular endothelial growth factor feature in these restorative programs, while chemokine receptor type 4 helps guide reparative vesicles to sites of injury. In models of cerebral ischemia such as middle cerebral artery occlusion, endothelial and progenitor-derived vesicles have been shown to protect the blood-brain barrier, in part by preserving tight junction proteins like zona occludens 1 and modulating von Willebrand factor release and angiopoietin-2 signaling.

This dual nature, pathological messenger and therapeutic agent, is precisely what makes the exosomes-X axis clinically attractive. On the diagnostic front, the review catalogs circulating endothelial exosome signatures with potential utility for early detection, prognosis, and disease stratification. Because exosomes in the blood carry molecular fingerprints of their cells of origin, profiling their microRNA, protein, and lipid content offers a non-invasive window into vascular health. A blood test that reads the endothelial exosome cargo could, in principle, identify patients at risk of developing multimorbidity long before symptoms appear, distinguish between inflammatory and metabolic disease subtypes, and track response to therapy over time. The authors argue that such signatures hold genuine promise as biomarkers, though they note that standardization of isolation and analytical methods remains an obstacle to clinical deployment.

On the therapeutic side, the review evaluates an emerging strategy: engineering endothelial exosomes to deliver therapeutic cargos and thereby restore vascular homeostasis. Exosomes offer several advantages over synthetic drug carriers. They are naturally biocompatible, cross biological barriers including the blood-brain barrier, can be surface-functionalized with targeting ligands, and can be loaded with RNA therapeutics, anti-inflammatory proteins, or small molecules. The authors describe multimodal formulations and advanced bioengineering platforms designed to tune vesicle tropism, cargo loading efficiency, and release kinetics. Engineered vesicles derived from healthy endothelium or endothelial progenitor cells could, for example, deliver anti-inflammatory microRNAs to atherosclerotic plaques or insulin-sensitizing cargos to metabolically active tissues, addressing several facets of multimorbidity with a single platform.

The concept of theragnostics, the fusion of therapy and diagnostics in one system, runs throughout the review. Because the same exosomal signatures that signal disease can be engineered into delivery vehicles that report on their biodistribution, ECs-exo could enable truly individualized treatment: profile the patient’s vesicle cargo, identify the dominant pathological pathway, select or engineer a matching therapeutic vesicle, and monitor the molecular response in circulation. The authors position this integrated approach as a way to improve diagnosis, prognosis, and personalized management of cardiometabolic multimorbidity, a condition whose complexity has largely defeated single-target drugs.

The review is candid about the challenges that stand between laboratory promise and bedside impact. Isolation and characterization protocols vary widely across studies, cargo sorting mechanisms are not yet fully mapped, dose standardization for vesicle therapeutics is unresolved, and large-scale manufacturing under good manufacturing practice conditions remains a formidable engineering problem. Distinguishing protective from pathological vesicle populations within a heterogeneous circulating pool is another unsolved puzzle. Nevertheless, the convergence of mechanistic insight, biomarker discovery, and bioengineering capability documented in the review suggests that the field is approaching an inflection point.

Funded by the National Natural Science Foundation of China, the Natural Science Foundation of Chongqing, and a Chongqing medical scientific research joint project, the work reflects a broader international push to understand extracellular vesicles as the body’s intercellular internet. If the exosomes-X axis framework proves correct, the endothelium’s nanoscale messengers may soon serve simultaneously as the earliest alarm for cardiometabolic disease, the yardstick of its progression, and the vehicle that reverses it. For the millions of people living with overlapping cardiovascular and metabolic disorders, that would represent a fundamental shift from managing separate diseases to treating the vascular system as the integrated whole it truly is.

Subject of Research: Endothelial cell-derived exosomes as diagnostic biomarkers and engineered therapeutics for cardiometabolic multimorbidity

Article Title: Exosomes-X axis: endothelial-derived extracellular vesicles for precision diagnosis and therapy in cardiometabolic multimorbidity

Article References: Tang, F., Zhu, S.-C., Zhou, H.-M., Liu, M., Yuan, W.-X., & Qiu, X.-W. (2026). Exosomes-X axis: endothelial-derived extracellular vesicles for precision diagnosis and therapy in cardiometabolic multimorbidity. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08946-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08946-w

Keywords: exosomes, endothelial cells, extracellular vesicles, cardiometabolic multimorbidity, type 2 diabetes, hypertension, atherosclerosis, stroke, microRNAs, endothelial dysfunction, targeted therapy, theragnostics